Skip to main content
. 2019 Nov 11;2019:9516279. doi: 10.1155/2019/9516279

Figure 4.

Figure 4

Clustered ranking plot of SUCRA values for efficacy vs. intolerability. AML, amlodipine; AZL, azilsartan; CAN, candesartan; FIM, fimasartan; LOS, losartan; TEL, telmisartan; PBO, placebo; S-AML, active enantiomer of amlodipine; CI, confidence interval.